Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibrx BiosciencesINBX +6.47%6 Pretax Margin % is % as of Mar. 2026. GuruFocus rates INBX with a GF Score™ of 6/100. The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Inhibrx Biosciences ranks worse than 93.01% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Inhibrx Biosciences Pretax Margin % Related Terms
Inhibrx Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Inhibrx Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INBX vs JBIO, NVAX, AVLN: Pretax Margin % Comparison
For the Biotechnology subindustry, Inhibrx Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Biosciences Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Inhibrx Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx Biosciences (INBX) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Inhibrx Biosciences and its competitors. According to the industry distribution chart, Inhibrx Biosciences ranks #878 out of 944 companies in the Biotechnology industry, placing it in the top 93%.
Is Inhibrx Biosciences' Pretax Margin % too high?
Inhibrx Biosciences' current Pretax Margin % is %. Based on the distribution chart, Inhibrx Biosciences ranks #878 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inhibrx Biosciences has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inhibrx Biosciences' Pretax Margin % compare to JBIO and NVAX?
According to the Biotechnology industry distribution chart, Inhibrx Biosciences ranks #878 out of 944 companies for Pretax Margin %. This places Inhibrx Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Inhibrx Biosciences and its competitors. Inhibrx Biosciences's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibrx Biosciences stock overvalued right now?
Inhibrx Biosciences (INBX) has a current Pretax Margin % of %. The current Pretax Margin % is %. Inhibrx Biosciences' overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Inhibrx Biosciences (INBX), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
6GF Score
Get the complete analysis for INBX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBX has been successfully added to your 
